MCID: HYP043
MIFTS: 48

Hyperandrogenism

Categories: Endocrine diseases

Aliases & Classifications for Hyperandrogenism

MalaCards integrated aliases for Hyperandrogenism:

Name: Hyperandrogenism 12 74 54 43 15 17 71
Hyperandrogenization Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11613
MeSH 43 D017588
UMLS 71 C0206081

Summaries for Hyperandrogenism

MalaCards based summary : Hyperandrogenism, also known as hyperandrogenization syndrome, is related to cortisone reductase deficiency and adrenal cortical adenoma. An important gene associated with Hyperandrogenism is CYP21A2 (Cytochrome P450 Family 21 Subfamily A Member 2), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Glucose / Energy Metabolism. The drugs Acarbose and Rosiglitazone have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and liver, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 74 Hyperandrogenism is a medical condition characterized by high levels of androgens in females. Symptoms... more...

Related Diseases for Hyperandrogenism

Diseases related to Hyperandrogenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 cortisone reductase deficiency 33.2 POMC HSD11B1 CYP21A2
2 adrenal cortical adenoma 32.7 POMC CYP21A2 CYP17A1 CYP11A1
3 3-beta-hydroxysteroid dehydrogenase deficiency 31.0 HSD3B2 CYP21A2
4 neurofibromatosis, type ii 31.0 SRD5A1 SHBG PRL POMC INS IGF1
5 acanthosis nigricans 30.9 SHBG PRL INSR INS IGF1 ADIPOQ
6 alopecia 30.9 SRD5A1 SHBG PRL IGF1 AR
7 adenoma 30.9 PRL POMC IGF1 CYP21A2
8 precocious puberty 30.8 GNRH1 CYP21A2 CYP19A1
9 ovarian cyst 30.7 PRL GNRH1 CYP19A1
10 lipid metabolism disorder 30.6 SHBG INSR INS HSD11B1 CYP21A2 ADIPOQ
11 infertility 30.6 SHBG PRL GNRH1 CYP19A1 AR
12 hyperinsulinism 30.5 SHBG INSR INS IGFBP3 IGFBP1 IGF1
13 central precocious puberty 30.5 IGF1 GNRH1
14 galactorrhea 30.5 PRL IGF1
15 premenstrual tension 30.5 POMC GNRH1
16 hyperprolactinemia 30.5 SHBG PRL POMC INS IGF1 GNRH1
17 aromatase deficiency 30.5 INS GNRH1 CYP19A1
18 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 30.5 POMC CYP21A2
19 hypoadrenalism 30.4 SHBG POMC
20 alopecia, androgenetic, 1 30.4 SRD5A1 SHBG CYP21A2 CYP19A1 AR
21 insulin-like growth factor i 30.3 SHBG PRL INSR INS IGFBP3 IGFBP1
22 hermaphroditism 30.3 WNT4 SHBG AR
23 pituitary tumors 30.3 PRL POMC IGF1
24 luteoma 30.3 SHBG PRL GNRH1 CYP21A2 CYP19A1
25 hyperglycemia 30.3 INSR INS IGF1 ADIPOQ
26 sleep apnea 30.3 INS IGF1 ADIPOQ
27 bone resorption disease 30.3 SHBG INS IGF1 CYP19A1
28 hyperthyroidism 30.2 SHBG PRL POMC INS IGF1
29 ovarian hyperstimulation syndrome 30.2 SHBG INS GNRH1 CYP19A1
30 donohue syndrome 30.2 INSR INS IGFBP3 IGF1
31 estrogen excess 30.2 SHBG PRL GNRH1 CYP19A1
32 intracranial hypertension 30.1 PRL HSD11B1 ADIPOQ
33 endometrial hyperplasia 30.1 CYP19A1 CYP17A1 AR
34 androgenic alopecia 30.1 SRD5A1 SHBG PRL INS IGF1 CYP19A1
35 leydig cell tumor 30.1 PRL GNRH1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
36 pituitary adenoma, prolactin-secreting 30.0 PRL POMC IGF1 GNRH1
37 androgen insensitivity syndrome 30.0 SRD5A1 SHBG INS AR
38 pituitary adenoma 30.0 PRL POMC IGF1 GNRH1
39 adrenal adenoma 30.0 POMC INS HSD11B1 CYP21A2 CYP17A1 CYP11A1
40 laron syndrome 29.9 IGFBP3 IGFBP1 IGF1 ADIPOQ
41 anovulation 29.9 SRD5A1 SHBG PRL INS IGFBP3 IGFBP1
42 adrenal carcinoma 29.9 POMC HSD3B2 CYP21A2 CYP17A1 CYP11A1
43 amenorrhea 29.9 WNT4 SHBG PRL POMC INS IGF1
44 sleep disorder 29.8 PRL POMC INS IGF1 ADIPOQ
45 hypoglycemia 29.8 PRL POMC INSR INS IGFBP3 IGFBP1
46 gender identity disorder 29.8 CYP19A1 CYP17A1 AR
47 endometriosis 29.7 WNT4 IGFBP1 GNRH1 CYP19A1 CYP17A1
48 transsexualism 29.6 CYP21A2 CYP19A1 CYP17A1 AR
49 gestational diabetes 29.6 SHBG INSR INS IGFBP1 CAPN10 ADIPOQ
50 cardiovascular system disease 29.6 SHBG INS IGFBP1 IGF1 HSD11B1 ADIPOQ

Graphical network of the top 20 diseases related to Hyperandrogenism:



Diseases related to Hyperandrogenism

Symptoms & Phenotypes for Hyperandrogenism

MGI Mouse Phenotypes related to Hyperandrogenism:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.37 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 GNRH1
2 growth/size/body region MP:0005378 10.32 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
3 behavior/neurological MP:0005386 10.31 ADIPOQ AR CYP11A1 CYP17A1 CYP19A1 CYP21A2
4 adipose tissue MP:0005375 10.29 ADIPOQ AR CAPN10 CYP17A1 CYP19A1 HSD11B1
5 cellular MP:0005384 10.29 ADIPOQ AR CYP11A1 CYP17A1 CYP19A1 HSD11B1
6 homeostasis/metabolism MP:0005376 10.28 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
7 immune system MP:0005387 10.28 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 CYP21A2
8 hematopoietic system MP:0005397 10.27 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 CYP21A2
9 cardiovascular system MP:0005385 10.26 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
10 integument MP:0010771 10.15 ADIPOQ AR CYP19A1 CYP21A2 GNRH1 HSD11B1
11 liver/biliary system MP:0005370 10.13 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 GNRH1
12 nervous system MP:0003631 9.93 ADIPOQ AR CYP11A1 CYP19A1 GNRH1 HSD11B1
13 muscle MP:0005369 9.91 ADIPOQ AR CYP11A1 CYP19A1 HSD11B1 IGF1
14 renal/urinary system MP:0005367 9.65 ADIPOQ AR CAPN10 CYP19A1 GNRH1 IGF1
15 reproductive system MP:0005389 9.36 AR CYP11A1 CYP17A1 CYP19A1 GNRH1 IGF1

Drugs & Therapeutics for Hyperandrogenism

Drugs for Hyperandrogenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
2
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
3
Simvastatin Approved Phase 4 79902-63-9 54454
4
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
5
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
6
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
10
Glucagon Approved Phase 4 16941-32-5
11
Drospirenone Approved Phase 4 67392-87-4 68873
12
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
13
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
14
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
15
Metformin Approved Phase 4 657-24-9 14219 4091
16
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
17
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
18
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
19
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
21
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
22
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
24
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
26
Enclomiphene Investigational Phase 4 15690-57-0
27
Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
28
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
29 Platelet Aggregation Inhibitors Phase 4
30 Hemostatics Phase 4
31 Mineralocorticoids Phase 4
32 Mineralocorticoid Receptor Antagonists Phase 4
33 Natriuretic Agents Phase 4
34 Diuretics, Potassium Sparing Phase 4
35 diuretics Phase 4
36 Lipid Regulating Agents Phase 4
37 Cardiac Glycosides Phase 4
38 Glycoside Hydrolase Inhibitors Phase 4
39 Anti-Infective Agents Phase 4
40 Anticholesteremic Agents Phase 4
41 Hypolipidemic Agents Phase 4
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
43 Antimetabolites Phase 4
44 Antioxidants Phase 4
45 Protective Agents Phase 4
46 Ergocalciferols Phase 4
47 Calciferol Phase 4
48 Vitamin D2 Phase 4
49 Free Radical Scavengers Phase 4
50 Mitogens Phase 4

Interventional clinical trials:

(show top 50) (show all 190)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
2 Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
3 Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome. Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
4 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
5 Study on the Effect of Combined Oral Contraceptive Therapy on Female Sexuality, Body Image and Mental Health Unknown status NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
6 The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
7 Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome Completed NCT03630341 Phase 4 Clomiphene Citrate 50mg;L-carnitine;Placebo Oral Tablet
8 Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
9 Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial Completed NCT00679679 Phase 4 Metformin;Placebo
10 Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions Completed NCT01626443 Phase 4
11 Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
12 Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial Completed NCT01279512 Phase 4 Metformin;Acarbose
13 Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome Completed NCT00437333 Phase 4 Metformin cloridrate
14 Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial Completed NCT01896492 Phase 4 NAC
15 The Effects of Vitamin D Supplementation on Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor in Vitamin D-Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial Completed NCT02460380 Phase 4 Vitamin D3
16 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
17 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
18 A Randomized, Double‐Blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Metabolic and Fertility Parameters in PCOS Women Completed NCT01721915 Phase 4 Vitamin D supplementation;Placebo
19 Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women Completed NCT00593294 Phase 4 OC - Drospirenone plus Ethynylestradiol
20 Therapeutic Effect of Vitamin D3 Supplementation to Clomiphene Citrate Resistant Polycystic Ovary Syndrome Women Completed NCT04010942 Phase 4 Vit D;Metformin;Clomiphene
21 Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients Recruiting NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
22 Continuous Versus Cyclical OCP Use in PCOS: A Pilot Study Recruiting NCT03819140 Phase 4 Yasmin
23 Ovarian Function in Women With Polycystic Ovary Syndrome Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
24 Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial Recruiting NCT04113889 Phase 4 Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily);Metformin, pioglitazone and placebo
25 Mild Stimulation Protocol Using Clomiphene Citrate / Gonadotropins Versus Conventional Stimulation Protocol for Women With PCOS Undergoing in Vitro Fertilization (IVF): a Prospective Non-randomized Controlled Trial Recruiting NCT04157725 Phase 4 mild stimulation protocol: oral Clomiphene Citrate;Conventional Stimulation Protocol: will receive FSH/HMG
26 Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome Terminated NCT00159575 Phase 4 Metformin / Placebo treatment for 4 months
27 Sleep, Metabolic, and Cardiovascular Dysfunction in Polycystic Ovary Syndrome Terminated NCT00203996 Phase 4 depot leuprolide plus estrogen/progestin replacement;pioglitazone
28 Pediatric Bipolar Collaborative Mood Stabilizer Trial Unknown status NCT00221429 Phase 3 lithium sodium divalproex
29 Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study Unknown status NCT02133755 Phase 3 Bromocriptine
30 Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome Unknown status NCT02255578 Phase 3 clomiphene citrate treatment
31 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
32 Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients : A Prospective Randomized Double Blind Placebo Controlled Trial Completed NCT00575601 Phase 3 SIMVASTATIN
33 Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents Completed NCT03981861 Phase 2, Phase 3 Metformin and Spironolactone
34 The Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Metabolic and Hormonal Disturbances in Polycystic Ovary Syndrome Patients Completed NCT03792984 Phase 3 Metformin;Placebo
35 The Use of an MMP Inhibitor, Doxycycline, to Reduce Ovarian Androgen Production and Restore Normal Cycling in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3 doxycycline
36 Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS Completed NCT01482286 Phase 3 Metformin
37 Metabolic Impact of Oral Contraceptives With or Without Metformin in Obese Adolescents With Polycystic Ovary Syndrome (PCOS) Completed NCT00283816 Phase 3 Metformin;Oral Contraceptive Pill;placebo
38 Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study Completed NCT00994812 Phase 3 metformin
39 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome Completed NCT00427700 Phase 3 clomiphene citrate;raloxifene
40 Metabolic and Endocrine Effects of Combination of Metformin and DPP-4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study Completed NCT02022007 Phase 3 Metformin XR;Saxagliptin;Saxagliptin-Metformin XR
41 Extended Clomiphene Citrate Regimen Versus Laparoscopic Ovarian Drilling for Ovulation Induction in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome Completed NCT02381184 Phase 2, Phase 3 clomiphene citrate
42 Study On The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) Completed NCT01577017 Phase 3 Letrozole
43 Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman. Recruiting NCT03334682 Phase 3 spironolactone;Doxycycline
44 Efficacy of Combined Letrozole-metformin in Comparison With Letrozole Only in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Recruiting NCT03135301 Phase 3 letrozole plus metformin;letrozole
45 Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women Recruiting NCT02635386 Phase 3 Exenatide once weekly (EQW );Dapagliflozin (DAPA);EQW plus DAPA;Dapagliflozin plus Glucophage (MET ER);Phentermine /Topiramate (PHEN/ TRP) ER
46 A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS) Recruiting NCT03480022 Phase 3 Liraglutide Pen Injector [Saxenda];Placebo Liraglutide Pen Injector
47 Determination if Oral DCI Administration to Women With PCOS Increases Total DCI Content in Urine and Blood... Terminated NCT00497653 Phase 2, Phase 3 DCI;Placebo
48 A Randomized Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) Treatment for Two Months Before Starting Ovulation Induction for in Vitro Fertilization (IVF) Terminated NCT00419913 Phase 2, Phase 3
49 Clomiphene Citrate Plus Cabergoline Versus Clomiphene Citrate Alone in Treatment of Polycystic Ovary Syndrome Associated Infertility Unknown status NCT02644304 Phase 2 Clomiphene citrate;Cabergoline
50 Effect of Non-surgical Periodontal Therapy Along With Myo-inositol on High Sensitivity C-reactive Protein and Insulin Resistance in Polycystic Ovary Syndrome Women Having Chronic Periodontitis: A Randomized Controlled Trial Unknown status NCT02633462 Phase 2 Myo-inositol

Search NIH Clinical Center for Hyperandrogenism

Cochrane evidence based reviews: hyperandrogenism

Genetic Tests for Hyperandrogenism

Anatomical Context for Hyperandrogenism

MalaCards organs/tissues related to Hyperandrogenism:

40
Ovary, Pituitary, Liver, Skin, Testes, Bone, Endothelial

Publications for Hyperandrogenism

Articles related to Hyperandrogenism:

(show top 50) (show all 3687)
# Title Authors PMID Year
1
Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. 54 61
20388053 2010
2
Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers. 54 61
20059433 2010
3
[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]. 54 61
20450755 2010
4
Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. 54 61
20070950 2010
5
Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. 54 61
20015405 2009
6
Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women. 54 61
19938957 2009
7
[Increased level of prostate-specific antigen: a diagnostic marker of hyperandrogenism women]. 54 61
20218317 2009
8
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. 54 61
19552904 2009
9
Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. 54 61
19403562 2009
10
Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. 54 61
19401323 2009
11
Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. 54 61
19401444 2009
12
The role of genetic variation in the lamin a/c gene in the etiology of polycystic ovary syndrome. 54 61
19401371 2009
13
KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. 54 61
19366843 2009
14
The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism. 54 61
19085698 2009
15
A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. 54 61
18851710 2009
16
Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. 54 61
19345914 2009
17
Nonhuman primates as models for human adrenal androgen production: function and dysfunction. 54 61
18683055 2009
18
[Effect of anti-Müllerian hormone on P450 aromatase mRNA expression in cultured human luteinized granulose cells]. 54 61
19570444 2009
19
An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. 54 61
19215335 2009
20
Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. 54 61
18840925 2009
21
Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. 54 61
19078868 2008
22
Polycystic ovary syndrome: treatment strategies and management. 54 61
19013863 2008
23
Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome. 54 61
19209619 2008
24
Cardiovascular risk in women with polycystic ovary syndrome. 54 61
18799960 2008
25
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. 54 61
18377903 2008
26
Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. 54 61
18602948 2008
27
Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. 54 61
18639784 2008
28
Insulin receptor autoimmunity and insulin resistance. 54 61
18556968 2008
29
Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. 54 61
18382906 2008
30
Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. 54 61
18362299 2008
31
Implications of polycystic ovary syndrome on oocyte development. 54 61
18181083 2008
32
Polycystic ovary syndrome and oocyte developmental competence. 54 61
18081939 2008
33
[Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome]. 54 61
18499961 2008
34
Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. 54 61
17825390 2007
35
Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 54 61
17885806 2007
36
Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. 54 61
17895317 2007
37
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 54 61
17984248 2007
38
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. 54 61
17954415 2007
39
Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. 54 61
17710731 2007
40
Phenotypic characteristics according to insulin sensitivity in non-obese Korean women with polycystic ovary syndrome. 54 61
17606307 2007
41
Association of the GAA1013-->GAG polymorphism of the insulin-like growth factor-1 receptor (IGF1R) gene with premature pubarche. 54 61
17442315 2007
42
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. 54 61
17582143 2007
43
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 54 61
17356050 2007
44
Lack of association between common polymorphisms in the 17beta-hydroxysteroid dehydrogenase type V gene (HSD17B5) and precocious pubarche. 54 61
17583494 2007
45
Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. 54 61
17374711 2007
46
Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. 54 61
17138841 2007
47
Childhood obesity and insulin resistance. 54 61
17709876 2007
48
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. 54 61
17426408 2007
49
Low-dose glucocorticoids in hyperandrogenism. 54 61
17628912 2007
50
Unexpected mosaicism of R201H-GNAS1 mutant-bearing cells in the testes underlie macro-orchidism without sexual precocity in McCune-Albright syndrome. 54 61
17101633 2006

Variations for Hyperandrogenism

Expression for Hyperandrogenism

Search GEO for disease gene expression data for Hyperandrogenism.

Pathways for Hyperandrogenism

Pathways related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 WNT4 POMC INS HSD3B2 CYP21A2 CYP17A1
2 12.35 INSR INS IGFBP3 IGFBP1 CYP19A1 CYP17A1
3
Show member pathways
12.29 INSR INS IGF1 ADIPOQ
4
Show member pathways
12.02 INSR INS IGF1 ADIPOQ
5
Show member pathways
11.99 WNT4 SRD5A1 IGF1 AR
6 11.75 POMC HSD3B2 CYP21A2 CYP11A1
7
Show member pathways
11.74 INSR INS ADIPOQ
8
Show member pathways
11.52 SRD5A1 HSD3B2 HSD11B1 CYP21A2 CYP19A1 CYP17A1
9
Show member pathways
11.48 HSD3B2 CYP19A1 CYP17A1
10 11.43 PRL INSR INS
11 11.38 IGF1 CYP19A1 AR
12 11.25 INSR INS IGF1
13 11.19 INSR INS IGF1 HSD3B2 CYP19A1 CYP17A1
14
Show member pathways
11.17 SRD5A1 POMC HSD3B2 HSD11B1 CYP21A2 CYP19A1
15 11.15 PRL HSD11B1 CYP11A1
16
Show member pathways
10.98 SRD5A1 CYP21A2 CYP17A1
17 10.93 IGFBP3 IGFBP1 IGF1
18 10.88 PRL POMC INS
19 10.8 SHBG GNRH1 AR

GO Terms for Hyperandrogenism

Cellular components related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 WNT4 PRL POMC INS IGFBP3 IGFBP1
2 extracellular region GO:0005576 9.85 WNT4 SHBG PRL POMC INS IGFBP3
3 insulin-like growth factor ternary complex GO:0042567 9.32 IGFBP3 IGF1
4 insulin-like growth factor binding protein complex GO:0016942 8.96 IGFBP3 IGF1
5 organelle membrane GO:0031090 8.92 SRD5A1 CYP21A2 CYP19A1 CYP17A1

Biological processes related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.07 PRL INSR INS IGF1 AR
2 oxidation-reduction process GO:0055114 10.07 SRD5A1 HSD3B2 HSD11B1 CYP21A2 CYP19A1 CYP17A1
3 cell-cell signaling GO:0007267 9.94 POMC INS GNRH1 AR
4 cellular protein metabolic process GO:0044267 9.88 PRL INS IGFBP3 IGFBP1 IGF1
5 glucose homeostasis GO:0042593 9.87 POMC INSR INS ADIPOQ
6 male gonad development GO:0008584 9.85 WNT4 SRD5A1 INSR AR
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 INSR INS IGF1
8 insulin receptor signaling pathway GO:0008286 9.83 INSR INS IGFBP1
9 cellular response to insulin stimulus GO:0032869 9.81 SRD5A1 INSR CAPN10 ADIPOQ
10 negative regulation of tumor necrosis factor production GO:0032720 9.79 POMC IGF1 ADIPOQ
11 steroid metabolic process GO:0008202 9.77 SRD5A1 HSD11B1 CYP21A2 CYP17A1 CYP11A1
12 activation of protein kinase B activity GO:0032148 9.76 INSR INS IGF1
13 positive regulation of mitotic nuclear division GO:0045840 9.73 INSR INS IGF1
14 positive regulation of MAPK cascade GO:0043410 9.72 INSR INS IGFBP3 IGF1 AR
15 sterol metabolic process GO:0016125 9.71 CYP21A2 CYP19A1 CYP11A1
16 cellular response to epinephrine stimulus GO:0071872 9.67 SRD5A1 ADIPOQ
17 positive regulation of glycolytic process GO:0045821 9.67 INSR INS IGF1
18 male sex determination GO:0030238 9.66 INSR GNRH1
19 neuron projection maintenance GO:1990535 9.65 INSR INS
20 progesterone metabolic process GO:0042448 9.65 SRD5A1 CYP17A1
21 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.64 IGFBP3 IGFBP1
22 cellular response to testosterone stimulus GO:0071394 9.63 SRD5A1 AR
23 prostate gland growth GO:0060736 9.63 CYP19A1 AR
24 positive regulation of glycogen biosynthetic process GO:0045725 9.63 INSR INS IGF1
25 positive regulation of respiratory burst GO:0060267 9.62 INSR INS
26 C21-steroid hormone metabolic process GO:0008207 9.61 HSD3B2 CYP11A1
27 female genitalia development GO:0030540 9.61 SRD5A1 CYP19A1
28 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.61 IGFBP3 IGF1 AR
29 androgen catabolic process GO:0006710 9.6 SRD5A1 CYP19A1
30 mineralocorticoid biosynthetic process GO:0006705 9.59 HSD3B2 CYP21A2
31 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.58 WNT4 AR
32 androgen biosynthetic process GO:0006702 9.58 SRD5A1 HSD3B2 CYP17A1
33 sex differentiation GO:0007548 9.56 WNT4 SRD5A1 CYP17A1 AR
34 positive regulation of glucose import GO:0046326 9.55 INSR INS IGF1 CAPN10 ADIPOQ
35 steroid biosynthetic process GO:0006694 9.43 SRD5A1 HSD3B2 CYP21A2 CYP19A1 CYP17A1 CYP11A1
36 glucocorticoid biosynthetic process GO:0006704 9.02 HSD3B2 HSD11B1 CYP21A2 CYP17A1 CYP11A1

Molecular functions related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.89 WNT4 POMC IGFBP1 AR ADIPOQ
2 oxidoreductase activity GO:0016491 9.87 SRD5A1 HSD3B2 HSD11B1 CYP21A2 CYP19A1 CYP17A1
3 heme binding GO:0020037 9.76 CYP21A2 CYP19A1 CYP17A1 CYP11A1
4 iron ion binding GO:0005506 9.73 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 CYP21A2 CYP19A1 CYP17A1 CYP11A1
6 insulin-like growth factor receptor binding GO:0005159 9.54 INSR INS IGF1
7 androgen binding GO:0005497 9.48 SHBG AR
8 insulin-like growth factor I binding GO:0031994 9.43 INSR IGFBP3 IGFBP1
9 insulin-like growth factor II binding GO:0031995 9.33 INSR IGFBP3 IGFBP1
10 steroid binding GO:0005496 9.26 SHBG HSD11B1 CYP21A2 AR
11 hormone activity GO:0005179 9.1 PRL POMC INS IGF1 GNRH1 ADIPOQ

Sources for Hyperandrogenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....